tiprankstipranks
Amneal Pharmaceuticals Inc (DE:2DT)
FRANKFURT:2DT
Germany Market
2DT
Amneal Pharmaceuticals
RESEARCH TOOLSreports

Amneal Pharmaceuticals (2DT) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

2DT Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Amneal
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2DT Stock 12 Month Forecast

Average Price Target

€17.06
▲(10.06% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Amneal Pharmaceuticals in the last 3 months. The average price target is €17.06 with a high forecast of €21.59 and a low forecast of €13.82. The average price target represents a 10.06% change from the last price of €15.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","22":"€22","9.25":"€9.25","13.5":"€13.5","17.75":"€17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.594261,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.059466190000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.82032704,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.25,13.5,17.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.3,15.784173923076924,16.268347846153848,16.752521769230768,17.23669569230769,17.720869615384615,18.20504353846154,18.689217461538462,19.173391384615385,19.65756530769231,20.141739230769232,20.625913153846152,21.110087076923076,{"y":21.594261,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.3,15.435343553076924,15.570687106153848,15.70603065923077,15.841374212307693,15.976717765384617,16.11206131846154,16.247404871538464,16.382748424615386,16.518091977692308,16.653435530769233,16.788779083846155,16.92412263692308,{"y":17.059466190000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.3,15.186179003076925,15.072358006153847,14.95853700923077,14.844716012307693,14.730895015384617,14.617074018461539,14.503253021538463,14.389432024615385,14.275611027692308,14.16179003076923,14.047969033846154,13.934148036923077,{"y":13.82032704,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€21.59Average Price Target€17.06Lowest Price Target€13.82
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:2DT
Salveen Richter
Goldman Sachs
Goldman Sachs
€16.41→€18.14
Buy
17.03%
Upside
Reiterated
08/10/26
Goldman Sachs Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)
UBS Analyst forecast on DE:2DT
Ashwani Verma
UBS
UBS
€19.87→€21.59
Buy
39.32%
Upside
Reiterated
08/03/26
Amneal Pharmaceuticals price target raised to $25 from $23 at UBSAmneal Pharmaceuticals price target raised to $25 from $23 at UBS
Piper Sandler Analyst forecast on DE:2DT
David Amsellem
Piper Sandler
Piper Sandler
€14.68
Buy
-5.26%
Downside
Reiterated
07/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI), Amneal Pharmaceuticals (NASDAQ: AMRX) and Erasca (NASDAQ: ERAS)
Barclays Analyst forecast on DE:2DT
Glen Santangelo
Barclays
Barclays
€13.82
Buy
-10.84%
Downside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Elevance Health (NYSE: ELV) and Tectonic Therapeutic (NASDAQ: TECX)
Truist Financial Analyst forecast on DE:2DT
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Verano Holdings (Other OTC: VRNO), Amneal Pharmaceuticals (NASDAQ: AMRX) and Molina Healthcare (NYSE: MOH)
J.P. Morgan Analyst forecast on DE:2DT
Chris Schott
J.P. Morgan
J.P. Morgan
€15.55
Buy
0.31%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Opus Genetics (NASDAQ: IRD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on DE:2DT
Salveen Richter
Goldman Sachs
Goldman Sachs
€16.41→€18.14
Buy
17.03%
Upside
Reiterated
08/10/26
Goldman Sachs Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)
UBS Analyst forecast on DE:2DT
Ashwani Verma
UBS
UBS
€19.87→€21.59
Buy
39.32%
Upside
Reiterated
08/03/26
Amneal Pharmaceuticals price target raised to $25 from $23 at UBSAmneal Pharmaceuticals price target raised to $25 from $23 at UBS
Piper Sandler Analyst forecast on DE:2DT
David Amsellem
Piper Sandler
Piper Sandler
€14.68
Buy
-5.26%
Downside
Reiterated
07/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI), Amneal Pharmaceuticals (NASDAQ: AMRX) and Erasca (NASDAQ: ERAS)
Barclays Analyst forecast on DE:2DT
Glen Santangelo
Barclays
Barclays
€13.82
Buy
-10.84%
Downside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Elevance Health (NYSE: ELV) and Tectonic Therapeutic (NASDAQ: TECX)
Truist Financial Analyst forecast on DE:2DT
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Verano Holdings (Other OTC: VRNO), Amneal Pharmaceuticals (NASDAQ: AMRX) and Molina Healthcare (NYSE: MOH)
J.P. Morgan Analyst forecast on DE:2DT
Chris Schott
J.P. Morgan
J.P. Morgan
€15.55
Buy
0.31%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (NASDAQ: AMRX), Concentra Group Holdings Parent, Inc. (NYSE: CON) and Opus Genetics (NASDAQ: IRD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amneal Pharmaceuticals

3 Months
Les SulewskiTruist Financial
Success Rate
13/18 ratings generated profit
72%
Average Return
+14.37%
Copying Les Sulewski's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +14.37% per trade.
1 Year
Les SulewskiTruist Financial
Success Rate
18/18 ratings generated profit
100%
Average Return
+64.51%
Copying Les Sulewski's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.51% per trade.
2 Years
Les SulewskiTruist Financial
Success Rate
18/18 ratings generated profit
100%
Average Return
+108.43%
Copying Les Sulewski's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +108.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2DT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
8
10
9
11
10
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
9
11
10
In the current month, 2DT has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2DT average Analyst price target in the past 3 months is 17.06.
Each month's total comprises the sum of three months' worth of ratings.

2DT Financial Forecast

2DT Earnings Forecast

Next quarter’s earnings estimate for 2DT is €0.20 with a range of €0.19 to €0.24. The previous quarter’s EPS was €0.26. 2DT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2DT has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2DT is €0.20 with a range of €0.19 to €0.24. The previous quarter’s EPS was €0.26. 2DT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2DT has Performed in-line its overall industry.

2DT Sales Forecast

Next quarter’s sales forecast for 2DT is €700.95M with a range of €686.42M to €710.09M. The previous quarter’s sales results were €690.25M. 2DT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2DT has Performed in-line its overall industry.
Next quarter’s sales forecast for 2DT is €700.95M with a range of €686.42M to €710.09M. The previous quarter’s sales results were €690.25M. 2DT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2DT has Performed in-line its overall industry.

2DT Stock Forecast FAQ

What is DE:2DT’s average 12-month price target, according to analysts?
Based on analyst ratings, Amneal Pharmaceuticals Inc’s 12-month average price target is 17.06.
    What is DE:2DT’s upside potential, based on the analysts’ average price target?
    Amneal Pharmaceuticals Inc has 10.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Amneal Pharmaceuticals Inc a Buy, Sell or Hold?
          Amneal Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Amneal Pharmaceuticals Inc’s share price target?
            The average share price target for Amneal Pharmaceuticals Inc is 17.06. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €21.59 ,and the lowest forecast is €13.82. The average share price target represents 10.06% Increase from the current price of €15.5.
              What do analysts say about Amneal Pharmaceuticals Inc?
              Amneal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Amneal Pharmaceuticals Inc?
                To buy shares of DE:2DT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.